Full Text
PCN63 EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) MUTATION TESTING AND FIRST LINE TREATMENT WITH GEFITINIB IS A DOMINANT STRATEGY IN THE TREATMENT OF ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC)

Abstract

Authors

G. de Lima Lopes

Back to Volume 14, Issue 3
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×